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Abstract
Objective: To characterize the current state of antifungal stewardship practices and perceptions of antifungal use among pediatric antimicro-
bial stewardship programs (ASPs).
Design: We developed and distributed an electronic survey, which included 17 closed-ended questions about institutional antifungal steward-
ship practices and perceptions, among pediatric ASPs.
Participants: ASP physicians and pharmacists of 74 hospitals participating in the multicenter Sharing Antimicrobial Reports for Pediatric
Stewardship (SHARPS) Collaborative.
Results: We sent surveys to 74 hospitals and received 68 unique responses, for a response rate of 92%. Overall, 63 of 68 the respondent ASPs
(93%) reported that they conduct 1 or more antifungal stewardship activities. Of these 68 hospital ASPs, 43 (63%) perform prospective audit
and feedback (PAF) of antifungals. The most common reasons reported for not performing PAF of antifungals were not enough time or
resources (19 of 25, 76%) and minimal institutional antifungal use (6 of 25, 24%). Also, 52 hospitals (76%) require preauthorization for
1 or more antifungal agents. The most commonly restricted antifungals were isavuconazole (42 of 52 hospitals, 80%) and posaconazole
(39 of 52 hospitals, 75%). Furthermore, 33 ASPs (48%) agreed or strongly agreed that antifungals are inappropriately used at their institution,
and only 25 of 68 (37%) of ASPs felt very confident making recommendations about antifungals.
Conclusions: Most pediatric ASPs steward antifungals, but the strategies employed are highly variable across surveyed institutions. Although
nearly half of respondents identified inappropriate antifungal use as a problem at their institution, most ASPs do not feel confident making
recommendations about antifungals. Future studies are needed to determine the rate of inappropriate antifungal use and the best antifungal
stewardship strategies.
(Received 15 April 2020; accepted 11 June 2020)
The prevention and management of invasive fungal infections is
challenging due to the difficulty in establishing a definitive diagno-
sis, limited therapeutic options, potential for treatment-related
adverse events, and high rates of morbidity and mortality.1,2 In
children, antifungal use has dramatically increased and shifted
to broader-spectrum agents.3,4 This increase is likely related to
higher numbers of immunocompromised patients at risk of inva-
sive fungal infections and the use of prophylactic and empiric
antifungal therapy in this population.5,6 Also, significant variability
exists in antifungal use across adult and pediatric hospitals, sug-
gesting possible misuse or overuse.7,8 The inappropriate use of
antifungals can lead to treatment failure, toxicities, increased costs,
and the emergence of resistance.9–11 Antimicrobial stewardship is a
widely established approach formonitoring and optimizing the use
of antimicrobials; however, most stewardship efforts have focused
on antibiotics and not antifungals.12,13 Antifungals have many
unique features: use in special populations (eg, immunocompro-
mised patients, premature neonates), use for infections that are
often difficult to microbiologically confirm, variable correlation
between in vitro and in vivo activity, high cost, and requirement
for therapeutic drug monitoring (TDM). Thus, the stewardship
strategies employed for these agents may differ from those for anti-
biotics. We aimed to characterize the current state of antifungal
stewardship among pediatric ASPs and the perception of ASPs
regarding inappropriate antifungal use, antifungal stewardship,
and antifungal resistance.
Methods
An electronic survey was developed based on published antimicro-
bial stewardship guidelines and specific antifungal stewardship
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interventions.14–17 An independent survey expert reviewed the
readability and design of the questionnaire; subsequently, the sur-
vey was pilot tested among a group of antimicrobial stewardship
physicians for relevance and content validity. The survey included
17 closed-ended questions exploring institutional antifungal stew-
ardship practices and perceptions (Supplementary Fig. 1 online).
The survey included questions about prospective audit and feed-
back (PAF) and preauthorization, since these are the core elements
of antimicrobial stewardship described in the 2016 Infectious
Diseases Society of America (IDSA) and the Society for Healthcare
Epidemiology of America (SHEA) guidelines.14 We also asked
about other antifungal stewardship elements and interventions
reported in the literature, including mandatory infectious diseases
consultations for fungemia, antifungal TDM, publication of insti-
tutional antifungal susceptibility reports, and the use of fungal
markers.15–17 Lastly, we included questions related to perceptions
around inappropriate antifungal use, antifungal stewardship,
and antifungal resistance. We used Likert-type scales, binary
options, and multiple choice answers, as appropriate, to capture
the perceptions around antifungal stewardship (Supplementary
Fig. 1 online).
The survey was distributed electronically among pediatric
ASPs of 74 hospitals participating in the multicenter Sharing
Antimicrobial Reports for Pediatric Stewardship (SHARPS)
Collaborative. A member of the antimicrobial stewardship team
(physician or pharmacist) completed the survey at each institution.
Data were collected from December 2018 through February 2019.
Reminders were sent to nonrespondents at 2–3-week intervals dur-
ing the data collection period. The first complete survey received
was included in the study and duplicate or incomplete surveys
from the same institution were excluded. Hospitals were deidenti-
fied prior to analysis.
We used descriptive statistics, including frequencies and pro-
portions, to summarize the survey responses. We compared anti-
fungal stewardship strategies and perceptions based on hospital
type, hospital beds, and geographic region using the χ2 test. The
statistical analysis was performed with JMP version 14.1 software
(SAS Institute, Cary, NC). Informed consent was obtained from
study participants. The study was approved by the Stanford
University School of Medicine Institutional Review Board.
Results
We received 68 unique responses from 74 hospitals, for a response
rate of 92%.We received surveys from 34 states and 2 international
sites. The respondents included 37 pediatric infectious diseases
physicians (54%) and 31 pharmacists (46%). Hospital characteris-
tics of the participating pediatric ASPs are summarized in Table 1.
Overall, 93% of ASPs (63 of 68) reported that they conduct 1 or
more antifungal stewardship activities. Of the 68 respondent ASPs,
32 (47%) use both core stewardship strategies: PAF and preautho-
rization of antifungals. Also, 20 ASPs (30%) require preauthoriza-
tion of antifungals alone, 11 (16%) perform PAF of antifungals
alone, and 5 (7%) do not perform any antifungal stewardship
activities.
Among pediatric ASPs, 43 of the 68 respondents (63%) perform
PAF of antifungals and 52 (76%) require preauthorization of 1 or
more antifungal agents. The characteristics of antifungal PAF and
preauthorization are shown in Table 2. No differences in antifungal
stewardship strategies were identified based on hospital type or
hospital beds. For those who do not audit antifungals, the most
common reasons for not performing PAF are insufficient time
or resources (19 of 25, 76%) and minimal institutional antifungal
use (6 of 25, 24%).
At 58 of the 68 respondent hospitals (85%), TDM of antifungals
is routinely performed, and 23 of these 58 programs (40%) have a
pharmacokinetics program to assist with this effort. Of the 58 hos-
pitals that reported antifungal TDM, all 58 (100%) perform TDM
for voriconazole and 46 (79%) perform TDM for posaconazole.
The target trough level reported for the treatment of suspected
invasive fungal infections varied across institutions (Fig. 1).
Among the responding hospitals, 10 (15%) reported that their hos-
pital has a policy mandating pediatric infectious diseases consulta-
tion for patients with fungemia. Among hospitals without a
mandatory consult policy, most reported that pediatric infectious
diseases consultations occur with >75% of the cases of fungemia
(67%, 39 of 58). Also, 53 of 68 institutions (79%) reported using
noninvasive fungal markers when evaluating for invasive fungal
infections. The most commonly used fungal markers among these
institutions were serum aspergillus galactomannan (53 of 53,
100%) and (1,3)-β-D-glucan (41 of 53, 77%). Only 14 hospitals
(20%) reported that they include antifungal susceptibilities as part
of their institutional antibiogram.
A summary of the ASPs perceptions about antifungal use and
resistance is shown in Figure 2, with additional details in
Supplementary Table 1 (online). Compared to children’s hospitals
within a hospital, ASPs from freestanding children’s hospitals are
more likely to agree or strongly agree that antifungals are inap-
propriately used at their institutions (60% vs 34%, P= .03).
Likewise, respondents from large-size hospitals (>300 beds) are
more likely to agree or strongly agree that antifungals are inap-
propriately used at their institution than medium- and small-sized
hospitals (67% vs 51% vs 25%, P= .02). The perception of inappro-
priate use did not differ based on the respondent’s role. ASPs in
hospitals that reported antifungal susceptibilities were more likely
to perceive antifungal resistance as problem at their institutions
(64% vs 35%, P= .04). Only 25 ASPs (37%) reported feeling very
confident in providing antifungal recommendations. Respondents




(N= 68), No. (%)
Type of hospital
Freestanding children’s hospital 35 (52)
Children’s hospital within a hospital 32 (47)











Note. ASP, antimicrobial stewardship.
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reported that having clinical guidelines specific for antifungal use
in children and better diagnostics would improve their level of con-
fidence in making antifungal recommendations (46%, 31 of 68 and
37%, 25 of 68, respectively). Furthermore, respondents perceived
hematology-oncology (32 of 68, 47%) and stem cell transplant
(15 of 68, 22%) as the services most likely to benefit from antifungal
stewardship interventions.
Discussion
Our survey revealed some of the antifungal stewardship practices
and perceptions in a cohort of pediatric ASPs. Most pediatric ASPs
have implemented some form of antifungal stewardship, and the
strategies employed are highly variable across surveyed hospitals.
Interestingly, although nearly half of respondents perceived inap-
propriate antifungal use as a problem at their hospital, many did
not feel confident in providing antifungal recommendations.
Specific stewardship strategies, including antifungal TDM and
fungal susceptibility reporting, appear to be less common and
may represent unique and important antifungal stewardship
opportunities.
According to our survey results, the core antimicrobial steward-
ship strategies, PAF and preauthorization, have been expanded to
include antifungals in most pediatric ASPs. Although these anti-
fungal stewardship interventions have been shown to successfully
reduce antifungal consumption in hospitalized patients, the best
approach to antifungal stewardship remains unknown.5,17–20
This lack of comparative data has likely led to the very heterog-
enous and hospital-specific approaches illustrated in this study.
Some studies have proposed that PAF andmore intensive steward-
ship strategies like daily PAF in combination with preauthorization
and formulary restriction, may be more effective in decreasing
antibiotic utilization.21,22 Whether the same is true for antifungals
is unknown. In our study, the use of preauthorization was more
common than PAF, which is considered relatively labor
intensive.14 Similar to prior reports evaluating antibiotic steward-
ship strategies, respondents reported that the biggest barrier
to implementing antifungal PAF was a lack of time and
resources.23–25 The frequency of antifungal monitoring varied
widely, with <10% of programs performing daily PAF. Whether
the absence of daily PAF reflects a lack of sufficient resourcing
or is a purposeful choice is uncertain; however, it may result in
missed opportunities to intervene and improve antifungal pre-
scribing. These findings highlight the importance of identifying
effective antifungal stewardship interventions to better utilize
and optimize current resources.
The characteristics of antifungal PAF and preauthorization var-
ied across hospitals. For example, the survey detected differences in
the types of antifungals monitored as part of PAF and restricted as
part of preauthorization programs. Broad-spectrum triazoles,
including voriconazole, posaconazole, and isavuconazole, were
commonly targeted as part of antifungal stewardship efforts.
ASPs may focus their efforts on these antifungals given the need
for TDM, potential toxicities, and their higher costs.26,27 However,
fluconazole may represent an important antifungal stewardship
target because it accounts for ~70% of antifungal prescriptions in
children4 and has been associated with inappropriate prescribing
in neonates and children.1,28
The TDM of azole medications is an important strategy to
ensure the appropriate use of antifungals and mitigate adverse
events.29 Most institutions responding to this survey routinely
monitor azole levels; however, TDM was the least commonly
monitored parameter among ASPs performing PAF of antifungals,
and only a few institutions reported having a pharmacokinetics
program to assist with antifungal TDM. These findings suggest
that most clinicians conduct TDM of antifungals without expert
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Amphotericin B (liposomal) 38 (88)
Isavuconazole 37 (86)





Pathogen–drug mismatch 39 (91)
Dose 38 (88)
Therapeutic drug monitoring 32 (74)
Most common recommendations
Stop antifungal 23 (53)
Convert intravenous to oral 21 (49)
Infectious diseases consult 21 (49)
Clarify indication 18 (42)
Therapeutic drug monitoring 17 (40)
Change dose 13 (30)




3 d per week 5 (12)
Once weekly 3 (7)








Amphotericin B (liposomal) 21 (40)
Amphotericin B (deoxycholate) 13 (25)
Fluconazole 3 (6)
Note. ASP, antimicrobial stewardship.
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guidance from pharmacists or ASP team members, which may
increase the risk for medication errors and suboptimal dosing.
Antifungals can be particularly challenging to use in children given
their unique pharmacokinetic and pharmacodynamic characteris-
tics. For example, studies have shown that up to 50% of antifungals
are inadequately dosed and that certain antifungals require multi-
ple dose adjustments to achieve therapeutic levels.5,28,30,31 Our
study revealed variability in the target therapeutic levels reported
across institutions, which suggests a lack of consensus in current
practices and an important opportunity for standardization.
Many of the survey respondents reported a lack of confidence in
making antifungal recommendations. This important finding
could be related to the limited diagnostic information available
to guide antifungal stewardship recommendations. Indeed, almost
40% of the respondents in our survey reported that having better
diagnostics would improve their level of confidence in making
antifungal recommendations. The absence of microbiological data
may limit the ability of ASPs to identify opportunities for discon-
tinuation or de-escalation of antifungals and contribute to pro-
longed courses of prophylactic or empiric antifungals. Previous
surveys have shown that de-escalation of broad-spectrum antibi-
otic therapy on the basis of culture results is one of the most
common antibiotic stewardship interventions.23 In contrast, our
study found that the recommendation to switch antifungals (ie,
Fig. 1. Voriconazole and posaconazole target therapeutic levels reported by pediatric antimicrobial stewardship programs.
Note. TDM, therapeutic drug monitoring.
Fig. 2. Perceptions about antifungal use and stewardship among pediatric antimicrobial stewardship programs.
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de-escalate therapy) was one of the least commonly reported inter-
ventions. As a surrogate for culture data, the use of noninvasive
fungal markers was common among the surveyed hospitals.
Prior studies have evaluated the use of noninvasive fungal markers
for the surveillance of invasive fungal infection in stem cell
transplant patients in an effort to shift from a prophylactic to a pre-
emptive approach and decrease potentially unnecessary antifungal
exposure.32–34 Further studies exploring the safety and utility of
these tests as part of antifungal stewardship interventions in the
pediatric population are warranted.
Inappropriate and unnecessary antifungal use was considered a
problem by most pediatric ASPs in this study. Oncology and stem
cell transplant were reported as the services that would benefit the
most from antifungal stewardship, likely because of the dispropor-
tionally higher antifungal utilization described in this population.7
Also, most ASPs in this cohort identified antifungal resistance
as a national problem, and to a lesser extent, an institutional prob-
lem. This perception may be due to the recent emergence of
multidrug-resistant Candida auris outbreaks in hospitals across
the United States.35 Most of these cases have been reported in
adults; therefore, respondents of this study may consider issues
of antifungal resistance as a national, rather than local, problem.
Only 20% of the hospitals reported antifungal susceptibilities as
part of the institutional antibiogram, and ASPs in these hospitals
were more likely to perceive antifungal resistance as a problem at
their institution. Possibly, therefore, resistant fungal organisms are
underreported or ASP teammembers are not aware of institutional
antifungal susceptibility trends. The emergence of antifungal resis-
tance has been increasingly recognized, and understanding the
local epidemiology is essential to developing institutional guide-
lines for antifungal prophylaxis and the empiric treatment of
fungal infections.
Our study has several limitations. First, these results may not be
generalizable to all pediatric hospitals. Although our response rate
was high, we only surveyed ASPs participating in the SHARPS
Collaborative, in whichmembers are actively involved in identifying
best practices for the use of antimicrobials. Therefore, we may be
overestimating the extent to which antifungal stewardship practices
are occurring. However, we were able to capture responses from
both freestanding children’s hospitals and children’s hospitals
within a larger adult hospital. In addition, ASPs from all 4
geographic regions in the United States and 2 international sites
in Europe were represented in our cohort. Another limitation is that
some of the responsesmay have been influenced by the respondent’s
familiarity with their institution’s resources and practices and may
represent perception rather than fact. Finally, we did not evaluate the
effectiveness of different antifungal stewardship interventions,
which should be further explored in future studies.
Although implementing antifungal stewardship has challenges,
it has the potential to decrease unnecessary and suboptimal anti-
fungal use, to reduce toxicities associated with inappropriate anti-
fungal use, and to prevent the emergence of antifungal resistance.
Currently, PAF and preauthorization are the main strategies used
by pediatric ASPs to perform antifungal stewardship. Future stud-
ies should evaluate the effectiveness and clinical impact of such
interventions. Optimization of antifungal dosing and TDM via
ASPs represent key components of antifungal stewardship in pedi-
atrics. Thus, future antifungal stewardship efforts should focus not
only on reducing unnecessary use but also on improving the qual-
ity of antifungal prescribing.
Supplementary material. To view supplementary material for this article,
please visit https://doi.org/10.1017/ice.2020.306
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